DSGN Key Statistics, Chart & Performance
The current stock price of DSGN is 10.21 USD. In the past month the price increased by 8.85%. In the past year, price increased by 110.52%.
DSGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DSGN. When comparing the yearly performance of all stocks, DSGN is one of the better performing stocks in the market, outperforming 96.26% of all stocks.
DSGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DSGN. While DSGN has a great health rating, there are worries on its profitability.
DSGN Financial Highlights
Over the last trailing twelve months DSGN reported a non-GAAP Earnings per Share(EPS) of -1.19. The EPS decreased by -40% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.85% | ||
| ROE | -33.77% | ||
| Debt/Equity | 0 |
DSGN Forecast & Estimates
10 analysts have analysed DSGN and the average price target is 13.26 USD. This implies a price increase of 29.87% is expected in the next year compared to the current price of 10.21.
DSGN Ownership
About DSGN
Company Profile
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 55 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Company Info
DESIGN THERAPEUTICS INC
6005 Hidden Valley Road, Suite 110
Carlsbad CALIFORNIA 92011 US
CEO: Joao Siffert
Employees: 55
Phone: 18582934900
DESIGN THERAPEUTICS INC / DSGN FAQ
What does DESIGN THERAPEUTICS INC do?
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 55 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Can you provide the latest stock price for DESIGN THERAPEUTICS INC?
The current stock price of DSGN is 10.21 USD. The price decreased by -3.41% in the last trading session.
Does DESIGN THERAPEUTICS INC pay dividends?
DSGN does not pay a dividend.
How is the ChartMill rating for DESIGN THERAPEUTICS INC?
DSGN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting DSGN stock to perform?
10 analysts have analysed DSGN and the average price target is 13.26 USD. This implies a price increase of 29.87% is expected in the next year compared to the current price of 10.21.
What is the employee count for DSGN stock?
DESIGN THERAPEUTICS INC (DSGN) currently has 55 employees.